During the past decade, progress in basic immunology has been impressive. In parallel,
whereas our understanding of the pathophysiology of acute graft-versus-host disease …

Minor histocompatibility (H) antigens are key molecules driving allo‐immune responses in
both graft‐versus‐host‐disease (GvHD) and in graft‐versus‐leukemia (GvL) reactivity in …

The adoptive transfer of donor T cells that recognize recipient minor histocompatibility
antigens (mHAgs) is a potential strategy for preventing or treating leukemic relapse after …

Minor histocompatibility (H) antigens are major targets of a graft‐versus‐leukemia (GVL)
effect mediated by donor CD8+ and CD4+ T cells following allogeneic hematopoietic cell …

Allogeneic stem cell transplantation (alloSCT) can be a curative treatment for hematological
malignancies. Unfortunately, the desired anti-tumor or graft-versus-leukemia (GvL) effect is …

The success of allogeneic hematopoietic stem cell transplantation (HSCT) depends on the
infusion of benign stem cells as well as lymphocytes capable of participating in a graft …

The outcome of allogeneic hematopoietic cell transplantation is influenced by
donor/recipient genetic disparity at loci both inside and outside the MHC on chromosome …

Ever since the discovery of the major histocompatibility complex, scientific and clinical
understanding in the field of transplantation has been advanced through genetic and …

Patients with malignant diseases can be effectively treated with allogeneic hematopoietic
stem cell transplantation (allo-SCT). Polymorphic peptides presented in HLA molecules, the …

Transplantation and pregnancy, in which two diploid genomes reside in one body, can each
lead to diseases in which immune cells from one individual target antigens encoded in the …